281 related articles for article (PubMed ID: 12453676)
1. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
2. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.
Vassar R; Kuhn PH; Haass C; Kennedy ME; Rajendran L; Wong PC; Lichtenthaler SF
J Neurochem; 2014 Jul; 130(1):4-28. PubMed ID: 24646365
[TBL] [Abstract][Full Text] [Related]
3. Effects of Folic Acid on Secretases Involved in Aβ Deposition in APP/PS1 Mice.
Tian T; Bai D; Li W; Huang GW; Liu H
Nutrients; 2016 Sep; 8(9):. PubMed ID: 27618097
[TBL] [Abstract][Full Text] [Related]
4. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
Das B; Yan R
CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.
Baranello RJ; Bharani KL; Padmaraju V; Chopra N; Lahiri DK; Greig NH; Pappolla MA; Sambamurti K
Curr Alzheimer Res; 2015; 12(1):32-46. PubMed ID: 25523424
[TBL] [Abstract][Full Text] [Related]
6. The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein.
Tabaton M; Tamagno E
Cell Mol Life Sci; 2007 Sep; 64(17):2211-8. PubMed ID: 17604999
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Transl Psychiatry; 2013 Jul; 3(7):e284. PubMed ID: 23880880
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.
Yan R; Fan Q; Zhou J; Vassar R
Neurosci Biobehav Rev; 2016 Jun; 65():326-40. PubMed ID: 27044452
[TBL] [Abstract][Full Text] [Related]
9. Beta-secretase: structure, function, and evolution.
Venugopal C; Demos CM; Rao KS; Pappolla MA; Sambamurti K
CNS Neurol Disord Drug Targets; 2008 Jun; 7(3):278-94. PubMed ID: 18673212
[TBL] [Abstract][Full Text] [Related]
10. Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease.
Stockley JH; O'Neill C
Cell Mol Life Sci; 2008 Oct; 65(20):3265-89. PubMed ID: 18695942
[TBL] [Abstract][Full Text] [Related]
11. Is It the Twilight of BACE1 Inhibitors?
Hrabinova M; Pejchal J; Kucera T; Jun D; Schmidt M; Soukup O
Curr Neuropharmacol; 2021; 19(1):61-77. PubMed ID: 32359337
[TBL] [Abstract][Full Text] [Related]
12. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
Lin X; Koelsch G; Wu S; Downs D; Dashti A; Tang J
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1456-60. PubMed ID: 10677483
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
14. Navigating the Maze of Alzheimer's disease by exploring BACE1: Discovery, current scenario, and future prospects.
Iram F; Shahid M; Ansari J; Ashraf GM; Hassan MI; Islam A
Ageing Res Rev; 2024 Jul; 98():102342. PubMed ID: 38762102
[TBL] [Abstract][Full Text] [Related]
15. Quercetin-3-O-glc-1-3-rham-1-6-glucoside decreases Aβ production, inhibits Aβ aggregation and neurotoxicity, and prohibits the production of inflammatory cytokines.
Tan S; Wu L; Liu J; Wu Z; Cheng Q; Qu Q; Zhu L; Yan Y; Wu H; Ling TJ; Liu RT; Yang S
Eur J Pharmacol; 2024 May; 970():176491. PubMed ID: 38503399
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia Inducible Factor-1α binds and activates γ-secretase for Aβ production under hypoxia and cerebral hypoperfusion.
Alexander C; Li T; Hattori Y; Chiu D; Frost GR; Jonas L; Liu C; Anderson CJ; Wong E; Park L; Iadecola C; Li YM
Mol Psychiatry; 2022 Oct; 27(10):4264-4273. PubMed ID: 35764706
[TBL] [Abstract][Full Text] [Related]
17. Early Animal Origin of BACE1 APP/Aβ Proteolytic Function.
Langeland JA; Baumann L; DeYoung EM; Varella RA; Mwenda N; Aguirre A; Moore DB
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785802
[TBL] [Abstract][Full Text] [Related]
18. Glycosaminoglycans from
Mycroft-West CJ; Devlin AJ; Cooper LC; Guimond SE; Procter P; Guerrini M; Miller GJ; Fernig DG; Yates EA; Lima MA; Skidmore MA
Mar Drugs; 2021 Apr; 19(4):. PubMed ID: 33916819
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibitors and modulators for Alzheimer's disease.
Wolfe MS
J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):89-98. PubMed ID: 22122056
[TBL] [Abstract][Full Text] [Related]
20. Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity.
Han X; Jing Z; Wu W; Zou B; Peng Z; Ren P; Wikramanayake A; Lu Z; Leblanc RM
Nanoscale; 2017 Sep; 9(35):12862-12866. PubMed ID: 28850143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
